Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels

Summary

High levels of thrombin-activatable fibrinolysis inhibitor (TAFI) are a supposed risk factor for thrombosis. However, results from previous studies are conflicting. We assessed the absolute risk of venous and arterial thromboembolism in subjects with high TAFI levels (>126 U/dl) versus subjects with normal levels, and the contribution of other concomitant thrombophilic defects. Relatives from four identical cohort studies in families with either deficiencies of antithrombin, protein C or protein S, prothrombin 20210A, high factor VIII levels, or hyperhomocysteinemia were pooled. Probands were excluded. Of 1,940 relatives, 187 had high TAFI levels. Annual incidences of venous thromboembolism were 0.23% in relatives with high TAFI levels versus 0.26% in relatives with normal TAFI levels (adjusted relative risk [RR] 0.8; 95% confidence interval [CI], 0.5–1.3). For arterial thrombosis these were 0.31% versus 0.23% (adjusted RR 1.4; 95% CI, 0.9–2.2). High levels of factor VIII, IX and XI were observed more frequently in relatives with high TAFI levels. Only high factor VIII levels were associated with an increased risk of venous and arterial thrombosis, independently of TAFI levels. None of these concomitant defects showed interaction with high TAFI levels. High TAFI levels were not associated with an increased risk of venous and arterial thromboembolism in thrombophilic families.

Keywords

Arterial thromboembolism - TAFI - venous thromboembolism

• References

• 1 Hendriks D, Scharpe S, van Sande M. et al. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989; 27: 277-285.
• 2 Eaton DL, Malloy BE, Tsai SP. et al. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-21838.
• 3 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-14484.
• 4 Bouma BN, Mosnier LO, Meijers JC, Griffin JH. Factor XI dependent and independent activation of thrombin activatable fibrinolysis inhibitor (TAFI) in plasma associated with clot formation. Thromb Haemost 1999; 82: 1703-1708.
• 5 Wang W, Boffa MB, Bajzar L. et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-27181.
• 6 Verdú J, Marco P, Benlloch S. et al. Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasma TAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD). Thromb Haemost 2006; 95: 585-586.
• 7 van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-2859.
• 8 Libourel EJ, Bank I, Meinardi JR. et al. Co-segregation of thrombophilic disorders infactor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. Haematologica 2002; 87: 1068-1073.
• 9 Eichinger S, Schonauer V, Weltermann A. et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004; 103: 3773-3776.
• 10 Martini CH, Brandts A, de Bruijne EL. et al. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Br J Haematol 2006; 134: 92-94.
• 11 Schroeder V, Kucher N, Kohler HP. Role of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with acute pulmonary embolism. J Thromb Haemost 2003; 01: 492-493.
• 12 Santamaria A, Martinez-Rubio A, Borrell M. et al. Risk of acute coronary artery disease associated with functional thrombin activatable fibrinolysis inhibitor plasma level. Haematologica 2004; 89: 880-881.
• 13 Schroeder V, Chatterjee T, Mehta H. et al. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 2002; 88: 1020-1025.
• 14 Juhan-Vague I, Morange PE, Aubert H. HIF-MECH Study Group. et al. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 2002; 22: 867-873.
• 15 Juhan-Vague I, Morange PE. PRIME Study Group. Very high TAFI antigen levels are associated with a lower risk of hard coronary events: the PRIME Study. J Thromb Haemost 2003; 01: 2243-2244.
• 16 Cellai AP, Antonucci E, Alessandrello Liotta A. et al. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit. Thromb Res 2006; 118: 495-500.
• 17 Morange PE, Tregouet DA, Frere C. The Prime Study Group. et al. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study. J Thromb Haemost 2005; 03: 1503-1510.
• 18 Brouwers GJ, Leebeek FW, Tanck MW. et al. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thromb Haemost 2003; 90: 92-100.
• 19 Silveira A, Schatteman K, Goossens F. et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-368.
• 20 Montaner J, Ribo M, Monasterio J. et al. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 2003; 34: 1038-1040.
• 21 Santamaria A, Oliver A, Borrell M. et al. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke 2003; 34: 2387-2391.
• 22 Leebeek FW, Goor MP, Guimaraes AH. et al. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 2005; 03: 2211-2218.
• 23 Ladenvall C, Gils A, Jood K. et al. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. Arterioscler Thromb Vasc Biol 2007; 27: 955-962.
• 24 Koeleman BP, Reitsma PH, Allaart CF. et al. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-1035.
• 25 Zoller B, Berntsdotter A, Garcia de Frutos P. et al. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-3523.
• 26 van Boven HH, Reitsma PH, Rosendaal FR. et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996; 75: 417-421.
• 27 Brouwer JLP, Veeger NJGM, Kluin-Nelemans HC. et al. Multicausal pathogenesis of venous thromboembolism. Evidence from a study in families with hereditary deficiencies of protein S, protein C or antithrombin. Ann Intern Med 2006; 145: 807-815.
• 28 Bank I, Libourel EJ, Middeldorp S. et al. Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med 2004; 164: 1932-1937.
• 29 Bank I, Libourel EJ, Middeldorp S. et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 2005; 03: 79-84.
• 30 Lijfering WM, Coppens M, van de Poel MHW. et al. The risk of venous and arterial thrombosis in hyper homocysteinemia is low and mainly depends on concomitant thrombophilic defects. Thromb Haemost 2007; 98: 457-463.
• 31 Brouwer JL, Veeger NJ, van der Schaaf W. et al. Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification. Br J Haematol 2005; 128: 703-710.
• 32 Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am Epidemiol 1996; 143: 1257-1265.
• 33 Schroeder V, Wilmer M, Buehler B. et al. TAFI activity in coronary artery disease: a contribution to the current discussion on TAFI assays. Thromb Haemost 2006; 96: 236-237.
• 34 Bertina RM, Koeleman BP, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
• 35 Danneberg J, Abbes AP, Bruggeman BJ. et al. Reliable genotyping of the G-20210-A mutation of coagulation factor II (prothrombin). Clin Chem 1998; 44: 349-351.
• 36 van Hylckama Vlieg A, van der Linden IK, Bertina RM. et al. High levels of factor IX increase the risk of venous thrombosis. Blood 2000; 95: 3678-3682.
• 37 Meijers JC, Tekelenburg WL, Bouma BN. et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342: 696-701.
• 38 Den Heijer M, Blom HJ, Gerrits WBJ. et al. Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis?. Lancet 1995; 345: 882-885.
• 39 Den Heijer M, Koster T, Blom HJ. et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 344: 759-761.
• 40 Rothman KJ, Greenland S. Modern epidemiology. Philadelphia: Lippincott-Raven Publishers 1998.;
• 41 Anderson Jr FA, Wheeler HB, Goldberg RJ. et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 15: 933-938.
• 42 Nordström M, Lindblad B, Bergqvist D. et al. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-160.
• 43 Thom TJ, Kannel WB, Silbershatz H. et al. Incidence, prevalence, and mortality of cardiovascular diseases in the United States. In: Hurst’s the Heart, 9th ed. \lMcGraw-Hill; 1998: 3-17.
• 44 Guimaraes AH, van Tilburg NH, Vos HL. et al. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol 2004; 124: 659-665.
• 45 Dommez A, Aksu K, Celik HA. et al. Thrombin activatable fibrinolysis inhibitor in Behcet’s disease. Thomb Res 2005; 115: 287-292.
• 46 Saibeni S, Bottasso B, Spina L. et al. Assessment of thrombin activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am J Gastroenterol 2004; 99: 1966-1970.